ANNAPOLIS, Md., Aug. 5 /PRNewswire-FirstCall/ -- PharmAthene, Inc.
(Amex: PIP) a biodefense company developing medical countermeasures against
biological and chemical threats, announced today that its financial results
for the second quarter of 2008 will be released on Tuesday, August 12,
2008.
PharmAthene management will be hosting a conference call to discuss its
second quarter 2008 financial results. The call is scheduled to begin at
4:30 p.m. Eastern Time on Tuesday, August 12, 2008 and will last
approximately 45 minutes.
The dial-in number within the United States is 800-706-7741. The
dial-in number for international callers is 617-614-3471. The participant
passcode is 48062719.
A replay of the conference call will be available for 30 days,
beginning at approximately 6:30 p.m. Eastern Time on August 12, 2008 until
approximately 11:50 p.m. Eastern Time September 9, 2008. The dial-in number
from within the United States is 888-286-8010. For international callers,
the dial-in number is 617-801-6888. The participant passcode is 76313724.
The conference call will also be webcast and can be accessed from the
company's website at http://www.pharmathene.com. A link to the webcast may be
found under the Investor Relations section of the website. The webcast will
be available for 30 days, or until approximately September 9, 2008.
About PharmAthene, Inc.
PharmAthene was formed to meet the critical needs of the United States
and its allies by developing and commercializing medical countermeasures
against biological and chemical weapons. PharmAthene's lead product
development programs include (1) SparVax(TM) -- a second generation
recombinant protective antigen (rPA) anthrax vaccine, (2) Valortim(TM) -- a
fully human monoclonal antibody for the prevention and treatment of anthrax
infection, (3) Protexia(R) -- a novel bioscavenger for the prevention and
treatment of morbidity and mortality associated with exposure to chemical
nerve agents, (4) RypVax(TM) -- a recombinant dual antigen vaccine for
plague, and (5) a third generation rPA anthrax vaccine. For more
information about PharmAthene, please visit http://www.PharmAthene.com.
SOURCE PharmAthene, Inc.
 back to top
Related links:
http://www.pharmathene.com
CONTACT:
Stacey Jurchison for PharmAthene, Inc.,
+1-410-269-2610, JurchisonS@PharmAthene.com
|
